Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beclomethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.65 |
| ▸ | PGR | P06401 | 5/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 4/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 2/20 | 0.65 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | IL5 | P05113 | 1/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexbudesonide SCHEMBL1302753 | 0.88 | NR3C1 (0.73) | NR3C1CYP3A4PGRHIF1AAR | |
| Ciclesonide SCHEMBL2070189 | 0.85 | NR3C1 (0.70) | NR3C1CYP3A4PGRHIF1AUSP2 | |
| Betamethasone Dipropionate SCHEMBL7120868 | 0.83 | NR3C1 (0.68) | NR3C1CYP3A4PGRHIF1AUSP2 | |
| SCHEMBL5396842 | 0.83 | NR3C1 (0.81) | NR3C1CYP3A4PGRHIF1AUSP2 | |
| SCHEMBL10352118 | 0.81 | CYP3A4 (0.65) | NR3C1CYP3A4PGRHIF1AAR | |
| SCHEMBL10799262 | 0.81 | CYP3A4 (0.65) | NR3C1CYP3A4PGRHIF1AAR | |
| Beclomethasone Dipropionate SCHEMBL1561582 | 0.81 | HIF1A (0.66) | NR3C1CYP3A4PGRHIF1AUSP2 | |
| Beclomethasone Dipropionate SCHEMBL3930412 | 0.81 | CYP3A4 (0.97) | NR3C1CYP3A4PGRHIF1AUSP2 | |
| Budesonide SCHEMBL1130417 | 0.81 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AAR | |
| Budesonide SCHEMBL13928654 | 0.81 | NR3C1 (1.00) | NR3C1CYP3A4PGRHIF1AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177574-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200131265-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190218288-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-10100116-B2 | FcγRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-2029173-B1 | FC RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-1534335-B9 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150344574-A1 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344575-A1 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| EP-1534335-B2 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS INC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-8968730-B2 | FcγRIIB specific antibodies and methods of use thereof | MACROGENICS INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20060013810-A1 | Humanized FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005115452-A2 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050260213-A1 | Fcgamma-RIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110474-A2 | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050215767-A1 | Fcgamma riib specific antibodies and methods of use thereof | MACROGENICS INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1534335-A2 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005018669-A1 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040185045-A1 | FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004016750-A2 | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-5823182-A | Medicament carrier for dry powder inhalator | GLAXO WELLCOME INC. (US) | 1998-10-20 | — | — | US | disclosed |